Please login to the form below
HBV
This page shows the latest HBV news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Vemlidy gets FDA approval for paediatric patients with chronic hepatitis B infection
HBV is a serious disease that attacks the liver and can cause chronic infection, cirrhosis of the liver, liver cancer and death in up to a third of patients. ... Vemlidy was approved by the FDA in 2016 as a once-daily treatment for adults with chronic
Latest news
-
Gilead announces positive Biktarvy data for HIV and hepatitis B
while HIV/HBV co-infection rates can reach 25% in areas where both viruses are endemic, such as Asia. ... Due to each virus affecting the other's natural history and response to therapy, HIV/HBV co-infection requires committed research.
-
Enanta takes legal action against Pfizer over Paxlovid patent infringement
Among these drugs, Enanta has produced therapies to address respiratory syncytial virus (RSV), human metapneumovirus (hMPV) chronic hepatitis B virus (HBV) and focused R&D efforts for COVID-19 early into
-
Vir Biotech launches new research programme for HIV and malaria prevention
The vaccinal antibody model is currently being incorporated across Vir’s existing candidate pipeline of potential SARS-CoV-2, chronic hepatitis B virus (HBV) and influenza A product cases.
-
Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
These three affiliates are developing an anti-CD19/CD3 candidate, an anti-CD38 enzyme inhibitor and an anti-HBV/CD3 antibody, respectively.
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
HBV) treatment Vemlidy compared to the same period last year.
More from news
Approximately 2 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Biotech profile: Tom Evans, CEO, Vaccitech.
Success in our clinical programs for flu, HPV and HBV vaccines could help shine a light on vaccines: currently a therapeutic modality that saves more lives per year than almost any
-
Deal Watch October 2018
Product / Technology. Deal Type. Headline. ($). Arrowhead/. Janssen (J&J). Development &commercialisation of ARO‐HBV, based on. ... The agreement is for the development of therapies to eliminate the hepatits B virus (HBV) in vivo using the genome
-
Pharma deals in April 2015
These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with chronic hepatitis B virus (HBV) infection.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
How the WHO hepatitis strategy measures up in the field
With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination by 2030 and reveals his dynamic
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
